NeuroSense Therapeutics (NRSN) vs Traws Pharma (TRAW)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
NeuroSense Therapeutics is the larger company by market cap ($7.0 million vs $7.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NRSN | TRAW |
|---|---|---|
| Share price | $3.70 | $0.455 |
| Market cap | $7.02M | $6.99M |
| 1-day change | -1.07% | -5.21% |
| EPS (TTM) | $-47.10 | $-1.71 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $26.64 | $3.27 |
| 52-week low | $3.56 | $0.43 |
| Distance from 52-week high | -86.11% | -86.09% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +2530.54% | +119.78% |
| Average volume | 21.29K | 569.02K |
| Shares outstanding | 1.90M | 15.37M |
| Employees | 17 | 4 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About NeuroSense Therapeutics
NRSN stock →NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 17 employees
About Traws Pharma
TRAW stock →Traws Pharma, Inc., a clinical-stage biopharmaceutical company, develops small synthetic molecules for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID-19 that are designed to address treatment resistance, such as TRX01 (Ratutrelvir), an inhibitor in development for the treatment of COVID-19; and Tivoxavir marboxil, an endonuclease inhibitor in development for the treatment of bird flu and seasonal influenza.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
NRSN vs TRAW FAQ
Which is bigger, NeuroSense Therapeutics or Traws Pharma?
NeuroSense Therapeutics (NRSN) is larger, with a market capitalization of $7.02M compared with $6.99M for Traws Pharma (TRAW).
Are NeuroSense Therapeutics and Traws Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.